Are there any subsets of patients where you would consider first-line dacomitinib for EGFR mutations positive NSCLC?
Are there specific mutations or co-mutations were you would consider use of this agent?
Community PollStarted
Do you use dacomitnib in the front line for EGFR mutant NSCLC?
22 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Cedars-Sinai Medical Center
Answered on
I continue to favor osimertinib as front line therapy for patients with EGFR mutation positive NSCLC. A retrospective analysis of response and benefit of osimertinib in some less common EGFR mutations was published, including G719X, L861Q, and S768I. The analysis showed clinical benefit with osimert...
Join for free or sign in to see the full answer